British Journal of Haematology | 2019
Venetoclax‐induced tumour lysis syndrome in acute myeloid leukaemia
Abstract
Burnett, A.K., Russell, N.H., Hills, R.K., Bowen, D., Kell, J., Knapper, S., Morgan, Y.G., Lok, J., Grech, A., Jones, G. & Khwaja, A. (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology, 16, 1295–1305. Creutzig, U., Dworzak, M.N., Bochennek, K., Faber, J., Flotho, C., Graf, N., Kontny, U., Rossig, C., Schmid, I., von Stackelberg, A. & Mueller, J.E. (2017) First experience of the AMLBerlin-Frankfurt-M€ unster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and alltrans retinoid acid. Pediatric Blood Cancer, 64, e26461. Iland, H.J., Collins, M., Bradstock, K., Supple, S.G., Catalano, A., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Campbell, L.J. & Hugman, A. (2015) Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. The Lancet Haematology, 2, 357–366. Kayser, S., Schlenk, R.F. & Platzbecker, U. (2018) Management of patients with acute promyelocytic leukemia. Leukemia, 32, 1277–1294. Kutny, M.A., Alonzo, T.A., Gerbing, R.B., Wang, Y.C., Raimondi, S., Hirsch, B.A., Fu, C.H., Meshinchi, S., Gamis, A.S., Feusner, J.H. & Gregory, J.J. Jr (2017) Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the Children’s Oncology Group Phase III historically controlled trial AAML0631. Journal Clinical Oncology, 35, 3021– 3029. Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S.M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E. & Specchia, G. (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. New England Journal of Medicine, 369, 111–121. Ortega, J.J., Madero, L., Mart ın, G., Verdeguer, A., Garc ıa, P., Parody, R., Fuster, J., Molines, A., Novo, A., Deb en, G. & Rodr ıguez, A. (2005) Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. Journal Clinical Oncology Official Journal American Society of Clinical Oncology, 23, 7632–7640. Sanz, M.A., Grimwade, D., Tallman, M.S., Lowenberg, B., Fenaux, P., Estey, E.H., Naoe, T., Lengfelder, E., B€ uchner, T., D€ ohner, H. & Burnett, A.K. (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 113, 1875–1891. Testi, A.M., Biondi, A., Coco, Francesco Lo, Moleti, M.L., Giona, F., Vignetti, M., Menna, G., Locatelli, F., Pession, A., Barisone, E. & De Rossi, G. (2005) GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood, 106, 447–453. Zhou, J., Zhang, Y., Li, J., Li, X., Hou, J., Zhao, Y., Liu, X., Han, X., Hu, L., Wang, S. & Zhao, Y. (2010) Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood, 115, 1697– 1702.